HIND - NASDAQ
Vyome Holdings, Inc.
$5.73
+14%Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
At a Glance
Live Snapshothind
Research Development Expenses
Last Annual Value
1.80M
3-Year CAGR
-11%
5-Year CAGR
-10%
10-Year CAGR
-17%
Vyome Holdings, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Vyome Holdings, Inc. NASDAQ:HIND | 1.80M | -8.0% | -6.5% | -10.0% | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 23.72M | -11.1% | 3.5% | 15.4% | |
 Codexis, Inc. NASDAQ:CDXS | 44.36M | -9.0% | -4.5% | 7.2% | |
 Nuvectis Pharma, Inc. NASDAQ:NVCT | 18.15M | 5.7% | 13.7% | N/A | |
 Sangamo Therapeutics, Inc. NASDAQ:SGMO | 112.67M | -21.6% | -13.4% | 5.6% | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 44.49M | -19.9% | -8.4% | 4.5% | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 104.24M | -4.0% | 1.9% | N/A | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 104.89M | 35.3% | 53.5% | N/A | |
 Anixa Biosciences, Inc. NASDAQ:ANIX | 5.07M | 2.1% | -3.9% | 12.5% | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 21.18M | 6.9% | 18.1% | 39.3% | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 17.22M | 30.8% | 37.1% | N/A |
Vyome Holdings, Inc. Fair Value Envelope
Related Guides
Continue your HIND research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.